Payment overview · 2025
General Payments
$2,055.79
110 reported records · 22 companies
Healthcare provider profile · identity verified
William H Crigler, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, SC · NPI 1043264765
Verified facts
What the public records show
CMS Open Payments records show William H Crigler, MD received $2,055.79 in general payments during 2025 across 110 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $301.17 | 14.7% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $236.24 | 11.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.80 | 9.8% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $177.86 | 8.7% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $145.83 | 7.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.73 | 6.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $98.53 | 4.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $93.49 | 4.5% | 5 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.21 | 4.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.05 | 4.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.55 | 3.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.48 | 3.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $60.76 | 3.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $59.83 | 2.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.98 | 2.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.05 | 2.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.03 | 1.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.52 | 1.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.90 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.47 | 0.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.19 | 0.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.12 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,055.79 | 110 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $199.32 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $177.86 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $177.86 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $175.98 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $175.98 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.07 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.50 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $150.54 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.73 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.62 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $98.53 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $93.49 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.05 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.48 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.17 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.98 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $62.49 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60.76 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $59.83 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.98 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.05 | 2 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.52 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 422 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 92 |
| Losartan Potassium | Losartan Potassium | 192 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 56 |
| Omeprazole | Omeprazole | 160 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 52 |
| Lisinopril | Lisinopril | 137 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 39 |
| Alprazolam | Alprazolam | 106 | 23 |
| Famotidine | Famotidine | 96 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 32 |
| Allopurinol | Allopurinol | 94 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 39 |
| Metformin Hcl | Metformin Hcl | 79 | 26 |
| Lorazepam | Lorazepam | 77 | 15 |
| Clonazepam | Clonazepam | 74 | 21 |
| Tramadol Hcl | Tramadol Hcl | 72 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 40 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 63 | 24 |
| Ozempic | Semaglutide | 62 | 16 |
| Ezetimibe | Ezetimibe | 59 | 24 |
| Gabapentin | Gabapentin | 57 | 23 |
| Jardiance | Empagliflozin | 52 | 11 |
| Eliquis | Apixaban | 51 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 26 |
| Furosemide | Furosemide | 47 | 22 |
| Metformin Hcl Er | Metformin Hcl | 47 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 18 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Farxiga | Dapagliflozin Propanediol | 41 | 13 |
| Prednisone | Prednisone | 41 | 27 |
| Trazodone Hcl | Trazodone Hcl | 41 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 20 |
| Potassium Chloride | Potassium Chloride | 39 | 15 |
| Ondansetron Odt | Ondansetron | 38 | 25 |
| Pregabalin | Pregabalin | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 11 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Temazepam | Temazepam | 35 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | 15 |
| Montelukast Sodium | Montelukast Sodium | 30 | 14 |
| Myrbetriq | Mirabegron | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Atenolol | Atenolol | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Armodafinil | Armodafinil | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Edecrin | Ethacrynic Acid | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,055.79 · 110 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ALVESCO, AZMIRO, Auvelity, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, EDARBI, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, HORIZANT, JATENZO, Kerendia, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, Sunosi, UBRELVY, VOQUEZNA, VYEPTI, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error